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Abstract
Soft tissue sarcomas of childhood are a group of
heterogeneous tumors thought to be derived from
mesenchymal stem cells. Surgical resection is effective
only in about 50% of cases and resistance to
conventional chemotherapy is often responsible for
treatment failure. Therefore, investigations on novel
therapeutic targets are of fundamental importance.
Deregulation of epigenetic mechanisms underlying
chromatin modifications during stem cell
differentiation has been suggested to contribute to
soft tissue sarcoma pathogenesis. One of the main
elements in this scenario is enhancer of zeste
homolog 2 (EZH2), a methyltransferase belonging to
the Polycomb group proteins. EZH2 catalyzes histone
H3 methylation on gene promoters, thus repressing
genes that induce stem cell differentiation to
maintain an embryonic stem cell signature. EZH2
deregulated expression/function in soft tissue
sarcomas has been recently reported. In this review,
an overview of the recently reported functions of
EZH2 in soft tissue sarcomas is given and the
hypothesis that its expression might be involved in
soft tissue sarcomagenesis is discussed. Finally, the
therapeutic potential of epigenetic therapies
modulating EZH2-mediated gene repression is
considered.
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methylation, methyltransferases
Introduction
Soft tissue sarcomas: a clinical challenge
Soft tissue sarcomas (STSs) are a group of heteroge-
neous malignant neoplasms thought to arise from mole-
cular lesions occurring during the differentiation of
mesenchymal stem cells (MSCs) [1]. STSs account for
less than 1% of all adult tumors and for about 15% of
all pediatric ones, with an estimated 10,520 new cases in
the US in 2010 [2,3]. A series of chromosomal translo-
cations have been identified as hallmarks of most STSs,
such as t(X;18)(p11.2;q11.2) in synovial sarcoma, t
(11;22)(q24;q12) in Ewing’s sarcoma, t(2;13)(q35;q14)
and t(1;13)(p36;q14) in alveolar rhabdomyosarcoma
(RMS). These chromosomal rearrangements result in
oncogenic fusion proteins that play direct roles in alter-
ing gene expression pattern in STS, promoting tumor
aggressiveness. Because of their infiltrating behavior,
only 50% of STSs are suitable for radical surgical resec-
tion. Moreover, a fraction of STSs are resistant to che-
motherapeutic agents, especially the metastatic forms
[4]. Doxorubicin, the drug used in standard single-agent
chemotherapy protocols for the treatment of metastatic
STS, results in only 20% to 25% response rates. Even
the combination of doxorubicin with other agents, such
as ifosfamide, has not dramatically improved the overall
5-year survival rate, which is no higher than 50% to 60%
[4]. Nevertheless, chemotherapy represents the only
viable strategy for palliation of symptoms in patients
with metastatic disease, improving their quality of life
[5]. New promising biological drugs, such as monoclonal
antibodies to insulin-like growth factor receptor (IGFR),
inhibitors of multityrosine kinases, and mammalian tar-
get of rapamycin (mTOR), have been introduced in STS
clinical trials (Table 1) [4]. However, disease stabilization
is still not seen in many patients, especially those
affected by peculiar histological variants or showing
poor-risk factors; it is reasonable to hypothesize that a
combination of cytotoxic chemotherapy with targeted
agents may be more appropriate to improve outcome in
STS patients. A novel class of therapeutic targets is
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Table 1 Targeted therapy clinical studies for soft tissue sarcoma (STS)
Biological molecular
agents
Molecular target(s) Clinical studies (phase) and clinical efficiency Reference
Tyrosine kinase inhibitors
(TKIs)
Imatinib mesylate (IM) c-Kit, PDGFR Phase II study: 53.7% of patients with GISTs showed a partial response,
27.9% of patients showed stable disease, 13.6% of patients showed early
resistance to imatinib, 5% of patients showed serious adverse events
[60]
Phase III study: confirmation of the effectiveness of imatinib as primary
systemic therapy for patients with incurable GIST. No advantages to
higher dose treatment were reported.
[61]
Sunitinib malate (SM) VEGF-R1, VEGF-R2, VEGF-R3, c-Kit,
PDGFR, Flt-3, CSF1, neurotrophic
factor receptors
Phase III study: 7% of patients with GIST showed partial response, 58%
had stable disease, 19% had progressive disease; 27.3 weeks was the
time-to-tumor progression for sunitinib vs 6.4 weeks for placebo.
Progression-free survival was similar.
[62]
Phase II study: 3-month progression-free rate of >40% for liposarcomas
leiomyosarcomas
[63]
Phase II study: 52% of patients showed metabolic stable disease, 20% of
patients achieved stable disease for at least 16 weeks, 47% of patients
achieved partial response
[64]
Phase II study (current): SM activity in patients with certain subtypes of
STS. The majority of these patients showed stable disease for 16 weeks.
[65]
Sorafenib VEGF-R2, VEGF-R3, c-Kit,
PDGFR, Raf/Mek/Erk
Phase II study: 14% of patients with angiosarcoma and 6% of patients
with leiomyosarcoma had a response, 64% of patients developed
intolerance at the drug dose used
[66]
Phase II study: 78% patients with vascular tumors showed disease
stabilization
[67]
Phase II study (current): antitumor activity and acceptable toxicity profile
in patients with antracycline-refractory STS
[68]
Pazopanib VEGF-Rs Phase II study: 12-week progression-free survival was reached by 44%
patients with leiomyosarcoma, 49% of patients with synovial sarcomas,
and 39% of patients with the other STS types
[69]
Nilotinib BCR/ABL, c-Kit, PDGFR,
CSF1R
Phase I study: nilotinib alone or in combination with imatinib was well
tolerated and showed clinical activity in imatinib-resistant GIST patients
[70]
Mammalian target of
rapamycin (mTOR)
inhibitors
Tensirolimus mTOR Phase II study: moderate toxicity and limited clinical activity [71]
Everolimus mTOR Phase II study: acceptable toxicity. Limited clinical activity in heavily
pretreated patients with bone and soft tissue sarcomas. The efficacy in
imatinib-refractory and sunitinib-refractory GIST is promising.
[72]
Ridaforolimus (AP23573) mTOR Phase I study: safety of the drug; 27% of patients showed stable disease. [73]
Phase II study: 29% of clinical benefit rate. Prolongation of survival. [74]
Phase III study (current) [75]
Insulin-like growth factor
(IGF) receptor antibodies
Figitumumab IGF-1R Phase I study: good tolerance of the drug [76]
R1507 IGF-1R Phase II study (current): R1507 is well tolerated. Significant activity has
been observed in Ewing’s sarcoma, RMS and OS with several dramatic
responses seen in Ewing’s sarcoma and RMS.
[77]
AMG479 IGF-1R Phase I study: absence of severe toxicities [78]
Mk-0646 IGF-1R Phase I study (current) [79]
CSF1 = colony stimulating factor 1; Flt = fms-related tyrosine kinase; GIST = gastrointestinal stromal tumor; OS = osteosarcoma; PDGFR = platelet-derived growth
factor receptor; RMS = rhabdomyosarcoma; VEGF = vascular endothelial growth factor.
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represented by epigenetic regulators, such as DNA
methyltransferases (DNMTs), histone acetylases (HATs),
histone deacetylases (HDACs), and histone methyltrans-
ferases (HMTs). Physiologically, all these enzymes work
in concert for regulating gene expression by modifying
the state of chromatin without altering DNA gene
sequences in order to obtain a proper tissue determina-
tion. Increasing evidence demonstrates that they play
key roles in human tumorigenesis, often being deregu-
lated in terms of expression and/or activity and leading
to silencing of essential regulators of cell proliferation
and differentiation. Indeed, from comparative analyses,
it appears that cancer genomes show different patterns
of epigenetic modifications as compared to normal cells.
Using inhibitory agents of all of these enzymes, it is pos-
sible to obtain pharmacological reversion of the tumor-
specific gene expression profile, as well as reactivation
of abnormally silenced tumor-suppressor genes in can-
cer cells [6]. Among these regulatory players, the histone
methyltransferase enhancer of zeste homolog 2 (EZH2)
is considered one of the most appealing epigenetic tar-
gets for therapy in human cancer [7].
The Polycomb group protein EZH2 in STS
EZH2 is one of the Polycomb group (PcG) proteins,
which repress expression of developmentally regulated
genes that induce tissue differentiation, such as homeotic
genes. PcG proteins help maintaining the undifferen-
tiated, multipotent phenotype of the embryonic stem cell
compartment [7-11]. In vertebrates, PcG proteins form
two different groups of multiprotein Polycomb repressor
complexes (PRCs), PRC1 and PRC2/3. EZH2 is the cata-
lytic unit of the PRC2/3 complex, the part involved in the
initiation of gene repression. EZH2 methylates lysine 27
of histone H3, thus generating the H3K27-trimethylated
epigenetic mark that is recognized by the PRC1 complex
for further, long-term chromatin modifications (Figure
1a) [8]. EZH2 is promptly downregulated during progeni-
tor cell differentiation, becoming undetectable in adult
specialized cells and tissues (Figure 1b) [12]. Conversely,
EZH2 is abnormally overexpressed in a wide range of
tumors as compared with corresponding normal tissues,
its level of expression being correlated with cancer
aggressiveness [7,13,14]. Moreover, the abundance of
EZH2 molecules induces the formation of more repressor
complexes and, by altering the balance between different
PcG components, may lead to the formation of tumor-
specific PRC complexes that show differential substrate
specificities [15]. As a result, not only the general level of
repression but also the specificity of repressed genes is
changed. EZH2 has recently been found aberrantly
expressed in aggressive and poorly differentiated breast
and prostate carcinomas [13,14], as well as in STS
[16,17]. EZH2 aberrant overexpression may be one of the
molecular lesions occurring in differentiating mesenchy-
mal stem cells (MSCs), which are thought to be the cells
of origin of STS [1]. It has been proposed that the pre-
sence of EZH2 in tumors with embryonal features and
stem-cell phenotype, such as STS, may explain their
undifferentiated and immature character. In view of
these data, EZH2 appears to be an attractive target for
investigation in STS.
EZH2 in RMS
RMSs are a heterogeneous group of STSs characterized
by features of skeletal muscle tissue and thought to be
caused by abnormalities occurring during the course of
myogenesis [18,19]. It prevalently affects pediatric
patients and accounts for almost 50% of all STSs [20].
Classically, RMSs are histologically subdivided in two
subtypes: the alveolar and embryonal forms. More
recently, it has been reported that a diagnosis of alveolar
RMS can be made only in the presence of two specific
molecular aberrations, namely t(2;13)(q35;q14) and/or t
(1;13)(p36;q14) chromosomal translocations resulting in
PAX3-FKHR and the rarer PAX7-FKHR oncogenic
fusion proteins, respectively [21]. These lesions have
been found in about 20% of all RMSs and in about 70%
of the RMSs with an alveolar histology [21,22]. True
alveolar RMSs are often metastatic at diagnosis, show
unresponsiveness to conventional therapy and have poor
prognosis, the long-term survival rate being < 25%
[23,24]. Fusion-negative RMSs include tumors with
embryonal histology and the remaining part of RMSs
with an alveolar histology [18]. Evidence for aberrant
overexpression of EZH2 in RMS samples has been
reported by Wang and colleagues [25] and by our studies
in RMS cell lines and primary samples [16]. We have
recently confirmed this finding in a large cohort of RMS
specimens, documenting that overexpression of EZH2 is
a hallmark of RMS, independently of the histological sub-
type [26]. It remains to be determined whether the level
of EZH2 expression correlates with the presence of
fusion proteins typical of the alveolar subtype. These
results are consistent with the observation that in a phy-
siological context EZH2 inhibits muscle differentiation of
normal myoblasts by silencing muscle-specific genes [27].
Among these genes are those encoding for promyogenic
microRNAs, such as miR-214 and miR-29. These belong
to a class of small RNAs that inhibits the translation of
selected mRNAs thus preventing their protein expression
[25,28]. Mir-26a is another microRNA acting to post-
transcriptionally repress EZH2 in normal myoblasts
undergoing differentiation (Figure 2a left panel) [29].
During differentiation, miR-29 is induced and targets the
PcG transcription factor yin yang 1 (YY1) mRNA pro-
moting its degradation (Figure 2a left panel). In the
absence of a myogenic stimulus and in RMS cells, EZH2
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is recruited together with HDAC1 by YY1 to repress tran-
scription of both myofibrillary genes [27,30] and miR-29
(Figure 2a right panel) [25]. Similarly, miR-214 is directly
repressed by EZH2 in undifferentiated committed myo-
blasts and, in turn, it is able to bring about negative feed-
back on EZH2 during myogenesis by targeting its
transcript [28]. A role for miR-26a and miR-29 in RMS
pathogenesis was confirmed by recent studies [16,25]. We
found that miR-26a is aberrantly downregulated in RMS
cell lines and primary tumors as compared to non-tumor
counterparts, and that miR-26a loss of expression is paral-
leled by an overexpression of EZH2 [16]. Similarly, miR-29
levels are reduced in tumor samples as compared with
control muscle tissues. This finding can be interpreted
considering that overexpressed EZH2 and YY1 are capable
to repress miR-29 transcription in RMS cells (Figure 2a)
Figure 1 Schematic representation of transcriptional gene repression by enhancer of zeste homolog 2 (EZH2). (A) In a mesenchymal
stem cell or in a soft tissue sarcoma (STS) cell, EZH2 interacts with suppressor of zeste 12 (SUZ12) and embryonic ectoderm development (EED),
the other core components of the Polycomb repressor complex 2 (PRC2) complex that is involved in the initiation of gene repression. By the
methyltransferase activity of EZH2, histone H3 is methylated on K27 thus generating the epigenetic mark H3K27Me3 that serves as a signal for
the recruitment of PRC1 complex. PRC1 DNA binding prevents the access of antagonistic chromatin remodeling factors, such as the SWI/SNF
complex, thus stabilizing the repressive state of the chromatin. The PRC2-associated activity of histone deacetylase (HDAC) and the interaction of
EZH2 with DNA methyltransferases (DMNTs) allow a further compaction of chromatin by means of histone deacetylation and DNA methylation,
respectively (synergism of epigenetic mechanisms). (B) During differentiation the level of EZH2 decreases with consequent reduction of PRC2
complex. H3K27 becomes hypomethylated and the SWI/SNF complex facilitates the DNA binding of tissue specific transcription factors (TF) that
engage histone acetyltransferase (HAT) to allow initiation of transcription.
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[25]. In agreement with the above observations, it has been
found that mi-R29 ectopic expression promotes RMS cell-
cycle arrest, myogenic cell differentiation and tumor
growth inhibition in a xenograft model [25]. Reduction of
miR-29 levels had been previously reported in a small
cohort of alveolar RMS [31]. Altogether, these findings
provide evidence for a key role of EZH2-mediated epige-
netic changes in RMS pathogenesis, which involve also
mutual interactions with microRNAs.
EZH2 in synovial sarcoma
Synovial sarcoma is a malignant cancer that affects pre-
valently young patients and represents almost 10% of all
STSs [32]. It is characterized by the typical translocation
t(X;18)(p11;q11) that generates the fusion between the
synovial sarcoma translocation, chromosome 18 (SS18
or SYT) gene on chromosome 18 and either synovial
sarcoma, X breakpoint 1, 2 or 4 (SSX1, SSX2 or SSX4)
genes on the X chromosome [33]. Previously reported
data showed that chimerical proteins SYT-SSX might
disrupt gene expression mechanisms by functionally
interacting with PcG proteins in synovial cells [34]. In
particular, SYT-SSX2 fusion protein induces down-
stream target-gene deregulation through epigenetic
mechanisms [35]. Recently, EZH2 has been found to
mediate the effects of SYT-SSX activity. Specifically,
SYT-SSX2 represses the expression of the tumor sup-
pressor gene early growth response 1 (EGR1), a regula-
tor of cell cycle, engaging EZH2 on the EGR1 promoter
in synovial sarcoma cells (Figure 2b). EGR1 repression
Figure 2 Possible mechanisms of deregulation of enhancer of zeste homolog 2 (EZH2) in soft tissue sarcoma (STS). (A) In normal
differentiating myoblasts (left panel) promyogenic miR-26a and miR-29 are normally expressed. MiR-26a and miR-29 target EZH2 and yin yang 1
(YY1) mRNAs, respectively, at the 3’ untranslated region (UTR) to induce their degradation. Conversely, in rhabdomyosarcoma (RMS) cells (right
panel) promyogenic miRNAs are downregulated and their loss of function is paralleled by the overexpression of EZH2 and YY1. YY1 recruits
EZH2 to repress the expression of miR-29, establishing a negative regulatory feedback loop. (B) In synovial sarcoma, the chimerical transcription
factor SYT-SSX engages EZH2 that leads to H3K27 trimethylation silencing tumor suppressor genes such as early growth response 1 (EGR1). (C) In
Ewing’s sarcoma the chimerical transcription factor Ewing sarcoma (EWS)/Friend leukemia integration 1 (FLI1) directly contributes to the
maintenance of high level of expression of EZH2.
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has been found to be associated with H3K27 trimethyla-
tion, and EZH2 and the PRC1 component BMI1 have
been shown to directly bind its promoter, thus support-
ing the existence of a novel epigenetic mechanism of
oncogenesis in synovial sarcoma [36]. This finding illus-
trates how a genetic lesion that generates an oncogenic
trascriptional regulator might exploit EZH2 and other
epigenetic regulators to sustain tumorigenesis.
EZH2 in Ewing’s sarcoma
Ewing’s sarcoma is an embryonal malignancy character-
ized by the t(11;22)(q24;q12) translocation which gener-
ates chimerical Ewing sarcoma (EWS)/ETS fusion
transcription factors. One of the most common fusion
protein found in patients affected by this tumor is EWS/
Friend leukemia integration 1 transcription factor (FLI1)
[37]. EZH2 is expressed at high levels in Ewing’s tumors
[17]. Studying the influence of EZH2 downregulation on
gene expression, Richter and colleagues found that
EZH2 is responsible for the undifferentiated phenotype
of Ewing’s sarcoma by maintaining a stemness gene
expression signature, inhibiting differentiation [17].
Strikingly, EWS/FLI1 has been found to induce the
expression of EZH2 by direct binding to its promoter
in both Ewing’s sarcoma cell lines and human MSCs
(Figure 2c) [17]. EWS/FLI1-dependent activation of
EZH2 seems to be specific, because the other compo-
nents of the PRC2/3 complex are not affected [38].
Notably, human MSCs seem to represent a permissive
environment for the expression of EWS/FLI1, which
induces features in these cells that recapitulate Ewing’s
sarcoma biology. This observation may implicate EZH2
as a coinitiator of Ewing’s sarcoma [39]. Data from
these studies offer an example of how a translocation-
derived fusion product takes advantage of EZH2 recruit-
ing this methyltransferase to drive tumor progression at
the expenses of differentiation.
Concluding remarks and future perspectives
Pediatric STSs, especially those metastatic at diagnosis,
are highly aggressive tumors for which there is still an
unmet medical need of more effective and less toxic
therapeutic approaches. The role of the epigenetic regu-
lator EZH2 in maintaining the embryonal cell phenotype
of STS, its overexpression in these cancers and its func-
tional interaction with many fusion proteins typical of
STS, suggest that EZH2 may represent both a potential
marker of undifferentiated precancerous cells and a rea-
sonable candidate therapeutic target in STS. Increasing
attention is focusing on epigenetic therapies that have
provided promising results in clinical trials for some
human tumors [40-42]. The clinical effectiveness of epi-
genetic therapies in human malignancies has been
recently proved by the observation that, in a randomized
phase III trial, the DNA hypomethylating agent azacyti-
dine prolonged overall survival of myelodysplastic
syndrome (MDS) patients compared to other standard
therapies [43]. The potential efficacy of epigenetic ther-
apy in STS is supported by preclinical studies employing
HDAC inhibitors [36,44-46]. Many studies on cell cul-
ture and animal models indicate that diverse epigenetic
processes synergize to control gene expression. Hence,
different kinds of epigenetic drugs, such as DNA-
demethylating agents and HDAC inhibitors, have been
included in combination treatment protocols [40,47]. It
is noteworthy that, in Ewing’s sarcoma cells, HDAC
inhibitor treatment in vitro induces downregulation of
EZH2 [17], as more recently confirmed in glioma [48],
gallbladder carcinoma [49] and acute myeloid leukemia
[50]. Consistently, in preclinical models of different can-
cers, the antitumor effect of EZH2 inhibition, obtained
through the methyltransferase inhibitor 3’-deazanopla-
nocin (DZNep), is enhanced by addition of HDAC inhi-
bitors [51-53]. DZNep has been shown to act by causing
depletion of PRC2 subunits with subsequent reactivation
of PRC2-silenced genes [54,55]. In addition, it has been
shown that the repressive function of EZH2 on gene
expression is strengthened by the role of DNMTs, with
which EZH2 physically interacts regulating their activity
[56]. In this view, additional usage of DNMTs inhibitors
in protocols targeting EZH2 might improve response in
some tumor contexts. In turn, since HMTs are also
active in non-proliferating cells, the inclusion of EZH2
inhibitors in combination regimens may overcome the
ineffectiveness of DNMTs inhibitors in quiescent cells.
On the other hand, it must be noted that, due to the
complexity of molecular crosstalk involved in epigenetic
control, the use of epigenetic drugs affecting a variety of
molecular networks entails the risk of unforeseeable
effects. For instance, despite their antiproliferative effects
in vitro, treatments employing either HDACs or DNA
methylation inhibitors have been recently reported to
increase in vivo the invasive capabilities of RMS cells
through upregulation of the prometastatic gene Ezrin
[57]. Major questions remain open on the in vivo
mechanism(s) of action of epigenetic drugs. Indeed, the
clinical response to azacytidine in terms of prolongation
of survival in MDS patients does not appear to be
directly correlated with methylation of specific tumor
suppressor genes, though methylation status has been
shown to correlate with poor survival [58]. Even if
future preclinical studies will better clarify the mechan-
isms of action of these drugs on gene expression, precli-
nical findings will need to be validated in humans [59].
Despite these unresolved questions, epigenetic therapy
is a promising approach for targeted anticancer thera-
pies in pediatric STS. Available evidence suggests that
targeting the methyltransferase EZH2 may be potentially
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able to restore physiological patterns of gene expression
in pediatric STS. In the future, modulation of EZH2
activity may provide a new line of intervention that
could be combined with epigenetic drugs acting on
other molecular targets and/or conventional cytotoxic
agents to treat these aggressive pediatric tumors.
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